Drugs / AZD0233
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06381466 | Apr 2024 → Dec 2025 | dilated cardiomyopathy | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0233 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06381466 ↗ |
| Route | Oral | “receive AZD0233 orally” NCT06381466 ↗ |